Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ.
Apar GuptaSachin R JhawarMutlay SayanZeinab A YehiaBruce G HafftyJames B YuShi-Yi WangPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Our findings suggest that cost-effective and clinically optimal treatment strategies are RT alone for standard-risk DCIS and observation for good-risk DCIS, with personalization on the basis of patient age and preference for RT. Hormonal therapy is likely suboptimal for most patients with DCIS.